retatrutide side effects trial results Warning against counterfeit "retatrutide" weight-loss drugs GLP-1 Side Effects: Retatrutide, Tirzepatide

Since its launch on October 11, 2024, the MindBody GLP-1 System has demonstrated outstanding market performance, exceeding expectations and establishing itself as a disruptive force in the weight management industry

However, there are nuances and specific safety considerations that every patient should be aware of

The FDA also recommends examining hard clinical endpoints such hepatic decompensations, transplant free survival, and all-cause mortality, although these results are not necessarily needed prior to drug approval given the long length of follow up potentially required

Anxiety and mood changes can occur, particularly during rapid weight loss phases

Finally, there is chemotherapy